Genentech prevails in Baxalta haemophilia treatment suit
Genentech has gained a win in a suit claiming that its haemophilia treatment Hemlibra infringes a patent owned by Takeda subsidiary, Baxalta, after a US federal judge held that parts of the patent were invalid.
Arthrex petitions Fed Circ again over ‘inferior officers’
Arthrex says that it did not get the “remedy” ordered by the US Supreme Court in its landmark case against Smith & Nephew.
PeriRx’s breach of licensing contract suit can’t prevail
Oral diagnostics company PeriRx has lost a patent licensing suit against the University of California and research company RNAmeTRIX, claiming that they had breached sublicensing agreements.
Eli Lilly avoids sanctions in Teva migraine treatment dispute
Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.
PTAB: Roche patent can’t evade IPR under Fintiv
Roche unit Chugai failed to persuade the US Patent Trial and Appeal Board that it should not institute inter partes reviews of a patent covering Actemra, a treatment for arthritis under the NHK/Fintiv rule.
AstraZeneca inks $730m licensing deal for rare heart disease treatment
Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy.
Scientist admits to Monsanto trade secret espionage
A former Monsanto employee has pled guilty to conspiring to steal trade secrets from the biotech company in order to share the information with the Chinese government.
Hatch-Waxman can’t offer ‘safe harbour’ defence in gene therapy case
Sarepta Therapeutics won’t be able to rely on a “safe harbour” provision to protect its gene therapy invention from a patent infringement suit from biotech Regenxbio and the University of Pennsylvania, a Delaware court has ruled.
Allele drops COVID-19 protein suit against Pfizer, BioNTech
Biotech Allele has dropped its lawsuit accusing Pfizer and BioNTech of infringing technology covering a fluorescent protein used in COVID-19 vaccines.
Hikma ‘skinny’ label does not infringe Amarin patents
Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.
